If I remember correctly, I read where 175 people had been treated with HDC with success (before Revimmune). Remember, this treatment was used at Stonybrook to treat MS patients before Accentia bought the license and started this trial. Dr. Gladstone, an oncologist, was treating MS patients at Stonybrook. He had previously worked at John Hopkins (before Stonybrook) and now he is at another New York hospital. Didn't Chris say that he had contacted Dr. Gladstone and he is no longer permitted to use the treatment on MS since Accentia bought the license and is conducting this trial.